PF 3845
PF 3845 性质
| 沸点 | 623.6±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.323±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 在DMSO中的溶解度≥45mg/mL |
| 酸度系数(pKa) | 14.14±0.40(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至棕褐色 |
PF 3845 用途与合成方法
Ki: 0.23 µM (FAAH)
PF-3845 (0.5 nM-10 μM; 40 min) inhibits human FAAH-1 (IC
50
=18 nM) in a concentration-dependent manner, and shows negligible activity against FAAH-2 (IC
50
>10 μM) in COS-7 cells.
PF-3845 (0.1-1000 μM; 48 h) significantly decreases the Colo-205 cell viability.
PF-3845 (1-30 mg/kg; p.o.) produces cannabinoid receptor-dependent reductions in inflammatory pain in rat.
PF-3845 (10 mg/kg; a single i.p.) selectively inhibits FAAH in mice for up to 24 hours.
PF-3845 (10 mg/kg; a single i.p.) causes a dramatic and sustained elevation in Anandamide (AEA) in mice.
| Animal Model: | Male Sprague-Dawley rats (200g- 250g) are injected CFA |
| Dosage: | 1, 3, 10, 30 mg/kg |
| Administration: | Oral administration |
| Result: | Caused a dose-dependent inhibition of mechanical allodynia with a minimum effective dose (MED) of 3 mg/kg. |
PF 3845 is a selective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 μM). Reduces inflammatory pain via a cannabinoid receptor-dependent mechanism. Highly efficacious and selective in vivo. D isplays no activity at FAAH-2 (IC50 >10 μM).
PF 3845 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-14380 | 1 mg | 278 | ||
| 2024-01-25 | HY-14380 | PF 3845 | 1196109-52-0 | 5mg | 512 |
